The Effect of Carrier Material on the Measured Resistance of Spores - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Effect of Carrier Material on the Measured Resistance of Spores
A biological indicator (BI) measures the effectiveness of the sterilization process to which it is subjected. Factors such as the test organism, the packaging, the culture material, and the test system all influence a BI's resistance. Carrier material is an often-overlooked factor that also influences BI resistance. The authors examine various solid and liquid carriers, describe their properties, and investigate how they influence BI resistance.

Pharmaceutical Technology

Liquid carriers

Figure 13
Liquid-carrier BIs generally consist of hermetically sealed glass ampuls filled with the inoculated liquid, which usually is a culture medium. The physical and chemical properties of the liquid influence spore resistance. Properties such as pH, ionic strength, the concentration of active ingredients, and the viscosity of these liquids can cause spores to clump. Spore clumping may lead to erratic results and higher resistance. The effect of pH is demonstrated by phase-contrast microscopy in Figures 13–15. Changes in the pH of some liqu-ids may cause spores to form aggregates. As the pH shifts from neutral to acidic, the spores may form larger aggregates. The size of the aggregates can protect spores in the center of these clusters, which results in a higher observed resistance. This resistance cannot be considered an artifact of experimental error because the chemistry of the liquid has a similar effect on the bioburden that naturally occurs in the product.

Figure 14
A survivor-curve test performed on clumped spores in a pharmaceutical product resulted in a rapid drop in population during the initial phase (i.e., the death of single spores or small clumps), followed by tailing because of the presence of large clumps of spores. (see Figure 16). Data such as these initially may seem troublesome, but they are critical when developing a product-sterilization cycle.

Liquid pharmaceutical product inoculated with spores used in BIs

Figure 15
The liquid spore carrier of a BI can be the pharmaceutical product itself. The excipients and active ingredients both can affect resistance. D-value studies performed on aqueous-based pharmaceutical products demonstrate that, in most cases, concentrations of active ingredients have little influence on the D-value. These results indicate that the excipients have the greatest impact on BI resistance. Test units using the same spores suspended in water for injection were prepared as a comparison (see Table III).

Figure 16
In the light of new and emerging materials and sterilization technologies, it is important to understand that spores are the only tool that can measure the lethality of a sterilization process effectively. Spores account for the substrate effect and the critical process parameters of the sterilization process itself.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here